Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 3
1948 4
1949 2
1950 2
1951 1
1952 1
1954 1
1956 1
1981 1
2001 1
2002 1
2003 1
2006 1
2008 1
2013 1
2014 2
2015 1
2018 3
2019 1
2020 3
2021 1
2022 4
2023 6
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy.
Böhnke N, Berger M, Griebenow N, Rottmann A, Erkelenz M, Hammer S, Berndt S, Günther J, Wengner AM, Stelte-Ludwig B, Mahlert C, Greven S, Dietz L, Jörißen H, Barak N, Bömer U, Hillig RC, Eberspaecher U, Weiske J, Giese A, Mumberg D, Nising CF, Weinmann H, Sommer A. Böhnke N, et al. Among authors: rottmann a. Bioconjug Chem. 2022 Jun 15;33(6):1210-1221. doi: 10.1021/acs.bioconjchem.2c00178. Epub 2022 Jun 3. Bioconjug Chem. 2022. PMID: 35658441 Free PMC article.
The genetic factors of bilaterian evolution.
Heger P, Zheng W, Rottmann A, Panfilio KA, Wiehe T. Heger P, et al. Among authors: rottmann a. Elife. 2020 Jul 16;9:e45530. doi: 10.7554/eLife.45530. Elife. 2020. PMID: 32672535 Free PMC article.
Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.
Gashaw I, Reif S, Wiesinger H, Kaiser A, Zollmann FS, Scheerans C, Grevel J, Piraino P, Seidel H, Peters M, Rottmann A, Rohde B, Arlt W, Hilpert J. Gashaw I, et al. Among authors: rottmann a. Eur J Endocrinol. 2023 Jul 10;188(7):578-591. doi: 10.1093/ejendo/lvad063. Eur J Endocrinol. 2023. PMID: 37306288 Free PMC article. Clinical Trial.
Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
Schmidt-Kraepelin C, Feyerabend S, Engelke C, Riesbeck M, Meisenzahl-Lechner E, Verde PE, Correll CU, Kluge M, Makiol C, Neff A, Lange C, Englisch S, Zink M, Langguth B, Poeppl TB, Reske D, Gouzoulis-Mayfrank E, Gründer G, Hasan A, Brockhaus-Dumke A, Jäger M, Baumgärtner J, Leucht S, Cordes J; COMBINE Study Group. Schmidt-Kraepelin C, et al. Lancet Psychiatry. 2022 Apr;9(4):291-306. doi: 10.1016/S2215-0366(22)00032-3. Epub 2022 Mar 8. Lancet Psychiatry. 2022. PMID: 35276079 Clinical Trial.
Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant.
Francke K, Chattopadhyay N, Klein S, Rottmann A, Krickau D, van de Wetering J, Friedrich C. Francke K, et al. Among authors: rottmann a. Eur J Drug Metab Pharmacokinet. 2023 Jan;48(1):75-87. doi: 10.1007/s13318-022-00805-5. Epub 2022 Dec 5. Eur J Drug Metab Pharmacokinet. 2023. PMID: 36469250 Clinical Trial.
Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of Endometriosis.
Hilpert J, Groettrup-Wolfers E, Kosturski H, Bennett L, Barnes CLK, Gude K, Gashaw I, Reif S, Steger-Hartmann T, Scheerans C, Solms A, Rottmann A, Mao G, Chapron C. Hilpert J, et al. Among authors: rottmann a. Drugs R D. 2023 Sep;23(3):221-237. doi: 10.1007/s40268-023-00427-5. Epub 2023 Jul 9. Drugs R D. 2023. PMID: 37422772 Free PMC article. Clinical Trial.
Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis.
Bäurle S, Nagel J, Peters O, Bräuer N, Ter Laak A, Preusse C, Rottmann A, Heldmann D, Bothe U, Blume T, Zorn L, Walter D, Zollner TM, Steinmeyer A, Langer G. Bäurle S, et al. Among authors: rottmann a. J Med Chem. 2019 Mar 14;62(5):2541-2563. doi: 10.1021/acs.jmedchem.8b01862. Epub 2019 Feb 22. J Med Chem. 2019. PMID: 30707023
41 results